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Abstract Trichosanthin (TCS) as a midterm abortifacient
medicine has been used clinically in traditional Chinese
medicine for centuries. Additionally, TCS manifests a host
of pharmacological properties, for instance, anti-HIV and
anti-tumor activities. TCS has been reported to inhibit cell
growth of a diversity of cancers, including cervical cancer,
choriocarcinoma, and leukemia/lymphoma, etc. This article
purported to review the various anti-tumor activities of
TCS and the mechanism of apoptosis it induced in these
tumor cells. These research progresses provide an insight
into cancer research and treatment as well as disclose new
pharmacological properties of the ancient but popular
Chinese medicine.
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Introduction
Trichosanthin (TCS) is a renowned traditional Chinese
medicine and still used in clinics in China for inducing
midterm abortion. TCS belongs to the family of plant
proteins known as ribosome-inactivating proteins (RIPs),
which can attack the ribosomes of eukaryotic cells by
virtue of their rRNA N-glycosidase activities [1–3]. This
results in the inhibition of protein synthesis and ultimately
the death of eukaryotic cells. RIPs are classified into two
major types [4–6]. Type I RIPs consist of only a single
rRNA-cleaving domain. Most of them are constructed of a
single intact polypeptide with a molecular weight around
30 kD. Type II RIPs comprise one or more rRNA cleaving,
amino-terminal domain(s), which are commonly called A
chain(s), and resemble type I RIPs. They are each linked by
a disulfide bond to a structurally unrelated carboxyl-ter-
minal domain called B chain [2].
TCS which possesses only one polypeptide chain is a
classic example of a type I RIP. As TCS is devoid of a cell-
binding B chain, it has less cytotoxic effects than most of
type II RIPs, such as ricin, and more selective toxicity to
cultured tumor cells, ovulated oocytes, HIV-infected
macrophages, and normal human macrophages. [7, 8].
Recently, more and more studies were focused on its anti-
tumor and apoptotic activities. The aim of this article was
to review the recent progress in research on the anti-tumor
activity of TCS.
Introduction to TCS
Trichosanthin (TCS), or Tin Hua Fen, is obtained from the
root tuber of Trichosanthes kirilowii Maxim belonging to
the Cucurbitaceae family. It has been employed for cen-
turies in traditional Chinese medicine as an abortifacient
drug in early and mid-gestation. Only in recent decades
were its enzymatic activities recognized as characteristic of
type I RIPs [9]. Although TCS has been adopted for
abortion purposes for hundreds of years in China, scientific
investigations on TCS commenced in around 1966 and
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many of the early studies were not published [10]. The first
publication on TCS appeared in 1976 [11]. Since then,
more and more biochemical and pharmacological investi-
gations have been conducted by researchers in Hong Kong,
China, and Western countries [6, 12].
TCS is composed of a single polypeptide chain with a
molecular weight of 27 kDa. Its amino acid sequence
demonstrates homology to the A chains of many type II
RIPs, such as ricin A chain [13–15]. It inhibits protein
synthesis through cleavage of the N–C glycosidic bond of
adenine 4324, the 4324th base of 28S rRNA. This action
renders the ribosome incapable of binding elongation fac-
tor 2 and therefore terminates translation [16, 17].
TCS owns a wide spectrum of biological and pharma-
cological activities (Table 1). It produces adverse effects
on reproduction in the mouse by causing follicular atresia
and degeneration of ovulated oocytes [7]. In fertilized
animals, TCS elicits death of syncytiotrophoblasts of pla-
cental villi, and consequently, the embryo fails to develop
[10, 11]. This action has been related to its uptake by
placental trophoblast cells. TCS also exhibits immuno-
modulatory (immunosuppressive), anti-tumor, anti-viral,
and anti-human immunodeficiency virus (HIV) activities
[6, 16]. Its anti-HIV activity is attributed to inhibition of
the replication of HIV and cytotoxicity to HIV-infected
macrophages and lymphocytes [8, 18]. The fact that TCS is
applied in the treatment of choriocarcinoma is consistent
with its abortive activity, since this tumor also originates
from fetal trophoblast cells [13]. The anti-tumor activity of
TCS is the main focus of this article.
Anti-tumor activity of TCS
Effects of TCS on choriocarcinoma
TCS is well known to exert deleterious effects on repro-
duction and is a clinical medicine for abortion. In the
mouse, it engenders follicular atresia and degeneration of
ovulated oocytes [7]. In fertilized animals, TCS causes
necrosis of the syncytiotrophoblasts of placental villi, and
consequently, the embryo fails to develop [19–21].
Therefore, the anti-tumor effects of TCS were first tested
on the cells of choriocarcinoma, a malignant trophoblastic
cancer, usually of the placenta (Table 2).
About two decades ago, Dai and colleagues conjugated
colloidal gold to TCS molecules and found that TCS spe-
cifically entered cultured trophoblast and choriocarcinoma
JAR cells via receptor-mediated endocytosis [22]. The
finding was subsequently corroborated by other investiga-
tors [23, 24]. The LDL receptor-related protein-1 (LRP1)
has been suggested as a major receptor for phagocytosis of
TCS in cultured JAR and BeWo cells, which might be the
molecular basis of the abortifacient and anti-choriocarci-
noma activities of TCS [25, 26]. Influx of calcium and
production of reactive oxygen species (ROS) were also
observed in TCS-treated JAR cells, and ROS production
might be a consequence of calcium ion signaling [27–29].
Effects of TCS on cervical cancer
When TCS was added to cultured tumor cells, it brought
about a reduction in the uptake of radioactive precursors
for protein synthesis [30]. This suggested that TCS killed
cells by virtue of its RIP activity. In addition, the anti-
tumor effect of TCS on cervical cancer has also been
revealed in many studies. Most of them are based on
in vitro experiments, with only a few based on observations
in vivo. Scientists first tested the toxic effects of TCS on
HeLa cervical cancer cells. TCS manifested significant
inhibitory effects [31, 32]. It heightened cytosolic calcium
and suppressed intracellular cAMP/protein kinase C (PKC)
levels via PKC inhibition [33–36]. Different from usual
RIP activities, TCS brings about apoptotic cell death in
HeLa cells, and activation of caspases 8, 9, and 3 has been
observed [37]. The upregulation of ER chaperone immu-
noglobulin heavy chain-binding protein (BiP) and C/EBP-
homologous protein (CHOP) and activation of caspase 4
suggest the participation of the endoplasmic reticulum
stress pathway in TCS-induced HeLa cell apoptosis [38].
Recent studies have also demonstrated the toxicity of TCS
on cervical cancer CaSki cells, and that TCS plays a role in
demethylation by inhibiting DNA (cytosine-5)-methyl-
transferase 1 (DNMT1) enzyme activity and DNM1
mRNA and protein expression in CaSki cells [39, 40]. The
demethylation of TCS in HeLa cells takes place via
attacking TSLCl and p16 genes [41, 42].
Only one article has reported the effect of TCS on
cervical cancer in vivo. Zhang et al. [43] established an
animal model of cervical cancer by repeated injections of
mouse U14 cell line into Kunming mice. TCS potentiated
the humoral immunity in mice at a dose of 0.2 mg/kg.
Table 1 Summary of various pharmacological activities of tricho-
santhin including anti-cancer activity
Pharmacological activity Ref. no.
Induction of atresia of ovarian follicles and inhibition of
steroidogenesis in gonadotrophin-primed immature mice
[7]
Induction of abortion [10, 11]
Anti-HIV and anti-HIV enzyme [16, 18]
Neurotoxicity [5]
Immunomodulatory [6]
Inhibition of protein synthesis [6]
RNA N-glycosidase activity [6]
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Effects of TCS on leukemia/lymphoma
Another cancer that has been reported to be sensitive to
TCS is leukemia/lymphoma. As early as in 1990s, TCS
was found to be toxic to leukemia/lymphoma cells in vitro
[8, 44]. A decade later, TCS was reported to exert an anti-
tumor action on chronic myelogenous leukemia K562 cells
and acute T cell leukemia Jurkat cells [38, 42, 45]. TCS
caused a down-regulation of p210Bcr-abl and its down-
stream signals, resulting in tyrosine kinase inhibition in
K562 cells [46]. Both PKC inhibition and caspase 3 acti-
vation are involved in TCS-induced apoptosis in K562
cells [45]. Under similar conditions, TCS is more toxic to
HUT78, MOLT-4, Jurkat, and CEM cells originating from
T lymphocytes and macrophages than Raji and Daudi cells
from B lymphoma [42].
Effects of TCS on other cancer cells
TCS has been reported to be effective against a variety of
other tumors, including hepatoma, colon carcinoma,
stomach cancer, lung cancer, breast cancer, prostate cancer,
and melanoma. Some early research reported that TCS did
not exert much toxicity to hepatoma cell lines, including
H35 and HepA-H [23, 31, 32]. However, when epidermal
growth factor (EGF) is conjugated to TCS, the immuno-
toxin EGF-TCS is toxic to hepatoma cells, for example,
BEL-7402, MCF-7, and BGC-823 [47]. In addition, EGF-
TCS also has in vivo anti-hepatoma effects when the
hepatoma animal model is constructed by injection of
BEL-7402 cells [48]. Actually, a TCS-based immunotoxin
or TCS conjugated with a specific cell binding molecule
has also been intensively studied. However, it is not the
main focus of this minireview [49].
Furthermore, dexamethasone enhances the effects of
TCS on apoptosis in HepG2 cells by inhibiting the NF-jB
signaling pathway, which highlights the possibility of
combined drug application of TCS and dexamethasone in
the clinical treatment of hepatoma [12]. Studies also dis-
close that TCS exhibits an anti-colon carcinoma effect in
both in vitro and in vivo experiments. When TCS gene is
cloned and expressed in colorectal carcinoma LoVo cells,
TCS evokes apoptosis in these cells [50]. Additionally, not
only colon carcinoma cell line CT-26, but also in vivo
colon carcinoma produced by Sw-1116 cells, is sensitive to
TCS toxicity [51, 52]. Furthermore, TCS produces toxic
effects on MCG803 cells of the stomach adenocarcinoma,
another cancer of the digestive system [53].
An animal model of lung caner was created by admin-
istration of A549 cells to nude mice. TCS prevented or
inhibited the process of lung tumorigenesis [54]. In another
in vivo experiment, TCS elicits an anti-tumor immune
response in a murine Lewis lung cancer model by boosting
the interaction between tumor suppressor in lung cancer 1
(TSLC1) and class-I MHC-restricted T cell-associated
molecule (CRTAM) [55]. TCS inhibits the proliferation of
MDA-MB-231 and MCF-7 cells and the growth of trans-
planted breast cancer in nude mice [56]. For prostatic
cancer, trichosanthin can induce apoptosis in RM-1 cells,
and the induction of apoptosis is a very important mecha-
nism of trichosanthin to inhibit this type of cancer [57].
TCS can also markedly inhibit melanoma cells by the
suppression of DNA synthesis in S phase and cell mitosis
as well as induction of cell apoptosis [58].
Table 2 Summary of TCS anti-tumor activities, including in vivo and in vitro experiments
System Tumor Cell line (in vitro) Animal (in vivo) Ref. no.
Female reproductive Choriocarcinoma JAR & BeWo [22–28]




Breast cancer MDA-MB-231 & MCF-7 Nude mouse
(transplanted)
[55]
Blood Leukemia & lymphoma K562, Jurkat, HUT78, Mo l-t 4,
Jurkat, CEM, Raji & Daudi
[8, 37, 40, 43–45]
Digestive Hepatoma H35, HepA-H & HepG2 [12, 23, 30, 31]
Colon carcinoma LoVo & CT-26 By Sw-1116 cells [49–51]
Stomach adenocarcinoma MCG803 [52]




Male reproductive Prostatic cancer RM-1 [56]
Other Melanoma B16 [57]
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Cellular mechanism of TCS
Cell entry mechanism of TCS
As a toxic protein, TCS needs to enter cells to inactivate
the eukaryotic ribosome through its RNA N-glycosidase
activity. The first step of this process is that TCS combines
and interacts with phospholipids in the cell membrane,
because TCS must get across the cell membrane before it
can enter the cytoplasm and exert its RIP function [25]. Xia
and colleagues investigated the difference between spon-
taneous and phospholipids-induced adsorption of TCS at
the air–water interface. The results were analyzed accord-
ing to the diffusion–penetration–rearrangement adsorption
model. TCS was specific for the negatively charged 1,2-
dipalmitoyl-sn-glycero-3-phosphoglycerol (DPPG). Another
experiment showed that electrostatic forces dominate
the interaction between TCS and negatively charged
phospholipid containing membranes under acid conditions.
In addition, both the pH value and the ionic strength can
influence the binding of TCS molecules [17, 59]. There-
fore, electrostatic forces and hydrophobic interaction are
proposed to be involved in the binding process of TCS. Xia
et al. [60] further investigated the interaction between TCS
and a phospholipid bilayer and found that the C-terminus
of TCS plays an important role in the interaction between
TCS and the membrane.
On the other hand, receptors are also regarded to be
necessary for TCS to enter cells [22–24]. TCS enters tro-
phoblasts, JAR cells, and choriocarcinoma BeWo cells by
binding to lipoprotein receptor-related protein, LRP1 [26].
It enters proximal tubule epithelial cells by binding
to megalin. It inserts into HIV via chemokine receptors
[61, 62].
Inhibition of tumor cell proliferation
TCS suppresses adenylyl cyclase activity and thus reduces
cyclic AMP (cAMP) levels in HeLa cells [36]. Interest-
ingly, a decrease in protein kinase C (PKC) level rather than
protein kinase A (PKA) level in these cells was observed.
This is different from the conventionally accepted mecha-
nism. In another experiment, Wang and colleagues reported
that both PKA and PKC activities were significantly
inhibited in TCS-treated HeLa cells, although a specific
PKA inhibitor failed to affect the effect of TCS, and PKC
activator/inhibitor significantly attenuated/enhanced the
inhibitory effect of TCS on cell proliferation [33]. The
inhibition of PKC was also found to be involved in
the apoptotic pathway induced by TCS in K562 cells [45].
The transcriptional factor cAMP response element-
binding (CREB) protein, a downstream molecule in cAMP/
PKA pathway, was found to participate in the TCS-induced
cell death pathway in HeLa cells [35]. CREB phosphory-
lation was significantly decreased by a cAMP inhibitor, but
not by a PKA inhibitor. All these data suggested that HeLa
cell proliferation was inhibited by TCS via suppression of
the PKC/MAPK signaling pathway.
Furthermore, TCS induced a rapid decline in nuclear
factor kappa B (NF-kB) and cyclooxygenase-2 (COX-2)
expression leading to apoptosis in hepatoma HepG2 cells
[12, 54]. The suppression of NF-kB and of COX-2 protein
has been suggested to be important for the antiproliferative
and proapoptotic effects on cancer cells [63, 64]. COX-2
may lie downstream of NF-kB, since the inhibition of
NF-kB can ensue in down-regulation of COX-2. TCS also
down-regulated p210 (Bcr-Abl), protein tyrosine kinase
(PTK), and heat shock protein 90 (Hsp90) in chronic
myelogenous leukemia K562 cells [46]. All these genes
and proteins are associated with proliferation of cancer
cells, and their inhibitors have been studied to treat a
variety of cancers in clinics [65–68].
All abovementioned data infer that TCS inhibits cell
proliferation in different tumor cells through different
pathways and mechanisms, which merit further in-depth
investigations. The mechanisms of TCS are summarized in
Fig. 1.
Apoptosis induced by TCS in tumor cells
Increase in Ca??ions and reactive oxygen species (ROS)
TCS treatment induced a transient elevation of intracellular
calcium and a slow rise of ROS in human chronic myeloid
leukemia cell line K562 [45]. However, calcium chelators
and antioxidants did not have a conspicuous effect on TCS-
induced apoptosis, suggesting that calcium changes and
ROS may not be implicated in TCS-mediated apoptosis in
K562 cells. In contrast, TCS elicited an increase in cyto-
solic calcium and induced apoptosis in HeLa cells [36].
Wang et al. [33] also confirmed that this apoptotic cell
death can be reduced by a specific calcium chelator, eth-
ylene glycol bis (2-aminoethyl) tetra (acetoxymethyl Ester)
(EGTA-AM). The aforementioned discrepancies may be
ascribed to the different types of cells studied. TCS may
induce apoptosis via distinctly different mechanisms in
different cells.
In another cell line, JAR, TCS stimulated the production
of ROS, which can be inhibited by the superoxide radical
anion (O2
-) scavenger superoxide dismutase, the H2O2
scavenger catalase, and the hydroxyl radical (OH-) scav-
enger mannitol [28]. The antioxidant Trolox and an
inhibitor of metal-facilitated OH- formation, diethylene-
triaminepentaacetic acid, also markedly inhibited TCS-
induced cell death [27]. All these results indicate that O2
-,
H2O2, and OH
- are involved in TCS-induced ROS
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formation in JAR cells. The increase in ROS is dependent
on the presence of both extracellular and intracellular Ca??
ions, and TCS-induced ROS production may be a conse-
quence of Ca?? signaling. In addition, TCS-induced acti-
vation of caspase 3 was initiated within 2 h; however,
TCS-induced production of ROS was initiated within
5 min. These findings suggest that the production of ROS
precedes the activation of caspase 3. The apoptotic mor-
phological changes of nuclei were also observed by two-
photon laser scanning microscopy in this experiment. The
finding that ROS is involved in the TCS-induced apoptosis
of JAR cells might provide new insight into the anti-tumor
and anti-HIV mechanism of TCS [27, 28].
Intrinsic and extrinsic apoptotic pathways
Key caspases in both intrinsic and extrinsic pathways,
encompassing caspases 8, 9, and 3, were activated in HeLa-
60 cells upon TCS treatment [38]. However, the Fas/Fas
ligand pathway was not involved as evidenced by a lack of
induction of Fas or Fas ligand and a lack of inhibitory
effect of anti-Fas antibody on TCS-induced apoptosis. The
involvement of mitochondria was demonstrated by the
reduction in mitochondrial membrane potential and release
of cytochrome c and Smac besides the activation of caspase
9 [38]. In addition, caspase 3 was corroborated to be the
major executioner caspase downstream to caspase 9, 4, and
8. Down-regulation of Bcl-2 was noted in TCS-treated
HeLa cells, and CREB is a possible upstream regulator of
Bcl-2 in TCS-induced cell apoptosis [33, 35]. On the other
hand, protein expression of Bax was up-regulated in TCS-
induced apoptosis of murine prostatic cancer RM-1 cells
[57].
Endoplasmic (ER) pathway and other mechanisms
TCS administration induced upregulation of the protein
chaperone BiP and transcription factor CHOP and also
activated caspase 4 in HeLa-60 cells, which for the first
time strongly supported the involvement of ER stress
pathway in TCS-induced apoptosis [38]. On the other hand,
inducible nitric oxide synthase (iNOS) mRNA expression
and protein levels were elevated in cells treated with TCS,
and nitric oxide (NO) production by cells was augmented
in the presence of TCS [65]. When L-NIL, the specific
inhibitor of iNOS, was added to suppress NO production
induced by TCS, OVA-specific cell death was significantly
inhibited; meanwhile, cellular thymidine incorporation was
restored to normal levels. These observations signify that
TCS could suppress antigen-specific T cell activation via
an NO-mediated apoptosis pathway. Additionally, TCS can
induce specific changes of cytoskeleton configuration
associated with the attenuated expression level of actin and
tubulin genes in apoptotic HeLa cells [69].
Conclusion
TCS, a midterm abortion medicine, is a type I RIP
endowed with a multiplicity of biological activities,
Fig. 1 The mechanism of TCS inhibiting proliferation and inducing apoptosis in tumor cells
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including anti-HIV and anti-tumor functions. TCS has been
found to be active against a variety of tumors, including
cervical cancer, choriocarcinoma, leukemia/lymphoma,
stomach cancer, colon cancer, hepatoma, breast cancer, and
prostate cancer. The toxic mechanisms of TCS on tumor
cells include inhibition of the proliferation and induction of
apoptosis of tumor cells, and the detailed mechanism varies
in different tumor cells. Further research on the anti-tumor
activities of TCS may not only shed light on cancer ther-
apy, but also on new pharmacological properties of ancient
Chinese medicines.
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